Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T, López-Cadenas F, Aires-Mejía I, Caballero-Berrocal JC, Ortega R, Redondo AM, Sánchez-Guijo F, Muntión S, García-Martín L, Albarrán B, Alonso JM, Del Cañizo C, Hernández-Hernández Á, Díez-Campelo M.
Jiménez-Solas T, et al. Among authors: albarran b.
Br J Haematol. 2019 Oct;187(1):93-104. doi: 10.1111/bjh.16013. Epub 2019 Jun 6.
Br J Haematol. 2019.
PMID: 31172513
Free article.
Clinical Trial.